Deslanoside

Summary

Deslanoside (CHEMBL1614) is an approved small-molecule anti-arrhythmia drug (ATC C01AA07) targeting ATP1A1; indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01AA07
• Targets: 1 (ATP1A1)
• Indications: 1 condition
• Chemistry: 943.1 Da · C47H74O19

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1614
Name	Deslanoside
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	28620
ChEBI	CHEBI:31468
ATC	C01AA07
Molecular formula	C47H74O19
Molecular weight	943.1
InChIKey	OBATZBGFDSVCJD-LALPQLPRSA-N

SMILES: C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2CC[C@]3([C@@H](C2)CC[C@@H]4[C@@H]3C[C@H]([C@]5([C@@]4(CC[C@@H]5C6=CC(=O)OC6)O)C)O)C)O)O[C@H]7C[C@@H]([C@@H]([C@H](O7)C)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)O

IUPAC name: 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-5-[(2S,4S,5S,6R)-4-hydroxy-6-methyl-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one

ChEBI definition: A cardenolide glycoside that is lanatoside C with the acetoxy group replaced by a hydroxy group.

Pharmacological roles (ChEBI): anti-arrhythmia drug, cardiotonic drug, EC 3.6.3.9 (Na+/K+-transporting ATPase) inhibitor.

Other ChEBI roles (chemical / environmental): metabolite.

Also known as: Cedilanid-d, Deacetylanatoside c, Deslanoside, Deslanosido, SID29215383, DESLANOSIDE, SID144205224, SID170465236, Lanatoside C, deslanoside

Patent coverage: 599 distinct patent families (2,112 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ATP1A1	sodium/potassium-transporting ATPase subunit α-1	Inhibition		84.2%	P05023

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Microtubule-associated protein tau, Cruzipain.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MAPT	7.1	Potency	79.4	nM	CHEMBL_ACT_4055912

Target pathways

Aggregated over 1 target gene(s): ATP1A1.

Top Reactome pathways

11 total, by targets touching each:

Pathway	Targets	Genes
Disease	1	ATP1A1
Transport of small molecules	1	ATP1A1
Muscle contraction	1	ATP1A1
Cardiac conduction	1	ATP1A1
Ion homeostasis	1	ATP1A1
Infectious disease	1	ATP1A1
Ion transport by P-type ATPases	1	ATP1A1
Potential therapeutics for SARS	1	ATP1A1
SARS-CoV Infections	1	ATP1A1
Viral Infection Pathways	1	ATP1A1
Ion channel transport	1	ATP1A1

Dominant GO biological processes

GO term	Targets
regulation of the force of heart contraction	1
regulation of sodium ion transport	1
intracellular sodium ion homeostasis	1
osmosensory signaling pathway	1
regulation of blood pressure	1
response to xenobiotic stimulus	1
establishment or maintenance of transmembrane electrochemical gradient	1
intracellular potassium ion homeostasis	1
negative regulation of glucocorticoid biosynthetic process	1
sodium ion transmembrane transport	1
sodium ion export across plasma membrane	1
negative regulation of heart contraction	1
positive regulation of heart contraction	1
positive regulation of striated muscle contraction	1
relaxation of cardiac muscle	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

6 molecules share ≥1 primary target. Top 6 by shared-target count:

Molecule	Source	Status	Shared targets
DIGOXIN	ChEMBL + PubChem	Phase 4 (approved)	ATP1A1
LANSOPRAZOLE	ChEMBL + PubChem	Phase 4 (approved)	ATP1A1
DIGITOXIN	ChEMBL	Phase 4 (approved)	ATP1A1
OMEPRAZOLE	ChEMBL	Phase 4 (approved)	ATP1A1
ROSTAFUROXIN	ChEMBL	Phase 2	ATP1A1
Pantoprazole	PubChem	Approved	ATP1A1